Raw nerve: Drugs may get costlier as prices of ingredients surge 30%

India's medicine prices are poised for a sharp increase due to a 30% surge in raw material costs, driven by container ship scarcity following the Iran war. This scarcity is hindering the movement of crucial ingredients from China, impacting local manufacturing and potentially forcing producers to pass on higher expenses to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tk2Gyhv
via IFTTT

Read More

India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25

With API exports hitting an impressive Rs 41,500 crore last fiscal year, India has outperformed its imports of Rs 39,215 crore. The government is pushing for a self-reliant economy via the Production Linked Incentive scheme, strategically aimed at cutting down import connections, notably with China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qGlBJYv
via IFTTT

Read More

Pharma exporters seek freight sops and logistical support as costs rise

As tensions in West Asia escalate, Indian pharmaceutical exporters are grappling with surging costs. In response, Pharmexcil is advocating for government interventions, including freight subsidies and enhanced logistical support. Meanwhile, companies are pivoting towards alternative shipping routes and ramping up their buffer stocks in anticipation of potential disruptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HAW7DLB
via IFTTT

Read More

Looking beyond seasonal sniffles: Protecting children's immunity from climate instability

Climate change is disrupting traditional illness patterns, affecting children's health. Savlon Swasth India Mission promotes proactive hygiene with the S.H.A.K.E. formula. This strategy encourages sanitizing, handwashing, doctor consultations, wound care, and nutritious meals. These habits build resilience against unexpected illnesses. The mission has positively impacted millions of children through hygiene education programs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EbVX8jG
via IFTTT

Read More

Cipla USA recalls Nilotinib anti-cancer capsules over manufacturing issue: USFDA

Cipla USA is recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules (150 mg and 200 mg) due to a manufacturing issue, the US Food and Drug Administration has said. The recall affects specific batches distributed in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zEldipu
via IFTTT

Read More

HLL Lifecare to expand AMRIT Pharmacies to 550 outlets by 2027

HLL Lifecare will significantly expand its AMRIT pharmacy network across India. The number of outlets will more than double to over 550 by December 2027. This initiative aims to make life-saving medicines and implants more affordable and accessible. Special focus will be on underserved and remote regions. The expansion involves an investment of Rs 100 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5SmdnUW
via IFTTT

Read More

India set to lead global homoeopathy with certified quality frameworks: Experts

India is set to lead the global homoeopathy market. Strong clinical expertise and practitioner networks are driving this growth. Internationally recognised quality certifications like AYUSH Premium Mark and NABL accreditation are key. Indian brands are now well-positioned to challenge established European dominance. This marks a significant shift in the global homoeopathy landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pObwAGH
via IFTTT

Read More